Is CGB preparing an Investor Presentation?
Yes, we have prepared a number of iterations of the Investor Presentation based on the changing landscape of our business model.
As the global and local Cannabis market/sector has been constantly changing and evolving, and we continue to be oversubscribed, the company has decided to wait until the new contractual arrangements have been completed and we have received shareholder approval for the updated resolutions, before we take the I.P. to print.
Have their been mistakes that have caused the company to release 12 Supplementary Prospectuses?
No, definitely not! As explained, in previous responses to the forum, the company has continued to conduct business, sign deals, vary existing contracts (noted in ASX releases) and create new partnerships that have required immediate changes and updates to the existing prospectus, as required by the ASX and ASIC. The market must be properly informed of any changes that alter/vary/change the original prospectus.
Why can't we relist and then conduct all the new changes?
The ASX require full disclosure and transparency from any company undergoing a re-compliance and change of activities. As the majority of our new deals have been in the negotiation/finalization stage for many months, these must be declared and then formalised during the suspension. They are considered as part of the original prospectus and its supplementary prospectuses and must be finalised before relisting. The Company does not expect any further major changes to occur now prior to the listing.
Why do the shareholders have to vote again?
As there has been a renegotiation and variation of agreement with our partners Medcan Australia (the 100% Merger not proceeding), which is a material change to the original prospectus, the ASX requires an EGM to be called to receive shareholder approval for the new changes to be discussed, explained and ratified by a formal vote prior to the company formally relisting.
